Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you make the most of staying home.
Visit the hub

A healthcare worker swabs a patient at a drive-through clinic in Montreal on March 31.

Paul Chiasson/The Canadian Press

Canada’s response to COVID-19 has been hampered for weeks by shortages of testing supplies and backlogs at laboratories, but the rollout of new Canadian-made testing technology means provinces may soon be able to increase testing in a significant way.

It remains unclear, however, whether health officials will follow the advice of many infectious disease experts and start using the new technology to expand testing and look for COVID-19 in people with just mild symptoms.

This week, the federal government, Alberta and Ontario signed deals with Spartan Bioscience Inc., a small Ottawa-based company that produces a hand-held DNA analyzer that can provide COVID-19 test results in about 30 minutes.

Story continues below advertisement

The latest on the coronavirus: Toll at central Ontario nursing home hits 14; Calgary police investigate virus-related threats

Canadian medical startups get major boost as Ottawa orders vital supplies in fight against COVID-19

Is the COVID-19 pandemic keeping you up at night? Here’s expert advice on how to get some sleep

The Spartan test has not yet been approved by Health Canada, but the company expects to get the green light soon and anticipates shipping thousands of test kits to clinicians within weeks.

The majority of conventional COVID-19 tests are conducted by inserting a long, specially designed nasopharyngeal swab far into a patient’s nostril. Swabs are then collected and sent to a hospital or public health laboratory, where they are processed in a large machine designed for polymerase chain reaction (PCR) tests.

Spartan’s rapid COVID-19 test, on the other hand, uses a throat swab produced by the company, which is then inserted into a single-use cartridge that goes into the company’s hand-held DNA analyzer.

The U.S. Food and Drug Administration has also approved new rapid COVID-19 tests in recent days, including a test produced by Illinois-based pharmaceutical giant Abbott Laboratories that can produce results in less than 10 minutes.

Such systems are ideal for smaller, more remote areas, according to Jim Woodgett, director of research at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. While the new rapid tests can’t process nearly the same volume of tests as large, hospital-based PCR machines, the hand-held DNA analyzers mean that small hospitals could get nearly instant results, without having to wait days for swabs to be sent to a central lab for processing.

A health care worker is seen at a COVID-19 testing area in Burnaby, B.C., on Wednesday.

JONATHAN HAYWARD/The Canadian Press

Eric Jan, a professor in the department of biochemistry and molecular biology at the University of British Columbia, said the speed of the new tests will be critical to helping ensure patients stay isolated to help contain the spread of COVID-19.

But public health agencies and hospital labs will still have to do much of the heavy lifting when it comes to large-scale COVID-19 testing. That means there’s still an urgent need to increase lab capacity and get more nasopharyngeal swabs and chemical reagents, which are used to complete tests.

Story continues below advertisement

Alison McGeer, director of the infectious diseases epidemiology research unit at the Lunenfeld-Tanenbaum Research Institute, said supplies are short because of unprecedented demand for these products from countries around the globe. Infectious disease outbreaks typically hit different parts of the world in waves and it’s unusual to see so many countries clamouring at once, Dr. McGeer said.

Across the country, hospitals, universities, governments and private companies are working to source testing materials and increase lab capacity, but the nature of COVID-19 testing means it takes time to speed up, Dr. McGeer said.

The PCR tests used by hospital and public health labs are “finicky” and need to be done in an extremely precise way, Dr. McGeer said. Everything from the chemical reagents that are used to the plastic in the nasal swabs must be exactly right, meaning that any new test supplies have to be checked and rechecked to ensure they produce accurate results.

While Canada and other countries will be able to sort out these supply chain issues, Dr. McGeer said, the process of ramping up takes time, which isn’t ideal during a global pandemic.

Then there’s the question of whether provinces will broaden the criteria for who can get a test. Countries such as South Korea have successfully flattened the curve by conducting widespread testing, including checks of asymptomatic close contacts of people with COVID-19. This approach has allowed officials to quickly identify and isolate new cases, slowing the rate of transmission.

But in Canada, test rationing means that in most parts of the country so far, the only people being tested are those with severe illness or those in other high-risk groups, such as health-care workers.

Prime Minister Justin Trudeau says thousands of suppliers answered a federal call for companies that can make gear and commodities Canada needs to treat people with COVID-19. The government is putting up $2 billion to buy personal protective equipment for health workers and medical equipment such as ventilators. The Canadian Press

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters.

In the interests of public health and safety, our coronavirus news articles are free for anyone to access. However, The Globe depends on subscription revenue to support our journalism. If you are able, please subscribe to globeandmail.com. If you are already a subscriber, thank you for your support.

Your subscription helps The Globe and Mail provide readers with critical news at a critical time. Thank you for your continued support. We also hope you will share important coronavirus news articles with your friends and family. In the interest of public health and safety, all our coronavirus news articles are free for anyone to access.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies